Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the RFVIIA variant (bay 86-6150) in hemophilia a or B with or without inhibitors

Category Primary study
JournalBlood
Year 2010
This article has no abstract
Epistemonikos ID: 2dbc41820baaa86df21783e9d62a70b04fc7728c
First added on: Feb 05, 2025